The startup develops a point-of-care device that enables continuous, non-invasive monitoring of chronic inflammatory diseases such as Crohn's disease and ulcerative colitis. By utilizing data analysis for predictive and preventive control, the device facilitates personalized treatment plans, improving disease management and patient quality of life.
Funding
$430K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic inflammatory diseases like Crohn's disease and ulcerative colitis require frequent monitoring to manage their condition effectively. Current diagnostic methods often involve invasive procedures and long waiting times, hindering timely intervention and personalized treatment adjustments.
Solution
Airbiometrics is developing a point-of-care solution for early detection and continuous monitoring of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. Their non-invasive approach analyzes specific biomarkers to reduce diagnostic time from months to hours, avoiding unnecessary invasive procedures like colonoscopies. The device enables decentralized monitoring, allowing patients to track their health status from home and facilitating timely adjustments to preventive treatments. By providing precise data on disease progression, Airbiometrics aims to improve patient quality of life, reduce healthcare system congestion, and enable the development of personalized preventative treatments.
Target Audience
The primary target audience includes patients with IBD, healthcare systems seeking to streamline diagnostic processes, insurance companies aiming to reduce healthcare costs, and pharmaceutical companies developing targeted therapies.
Features
- Non-invasive sample collection, eliminating the discomfort associated with traditional diagnostic tests.
- Rapid analysis of IBD-specific biomarkers, reducing diagnostic time to a few hours.
- Point-of-care device enabling decentralized monitoring from the patient's home.
- Data analysis for personalized treatment adjustments and preventative care.
- Classification of cases based on severity to prioritize resources and avoid unnecessary colonoscopies.